The global AI In Life science Analytics Market is projected to be valued at USD 1.9 billion in 2024 and reach USD 3.6 billion by 2030, growing at a CAGR of 10.9% according to a new report by The ...

Palvella Therapeutics Inc. Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral ...

First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our ...

Atea defines working capital as current assets less current liabilities. See the Company’s condensed consolidated financial statements in its Quarterly Report on Form 10-Q for the three months ended ...

Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 - - Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 - - Cash position ...

Proof-of-mechanism has been established for TNG260 based on pharmacodynamic data from on-treatment patient biopsies, with ...

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, ...

Although current stock market conditions ... we plan to report our 40% interest on a one-quarter lag. As a result, our actual reported adjusted EBITDA will differ from pro forma results during ...